How Rejuran and PDRN Skin Boosters Actually Work: The Mechanism Explained

6 days ago

5 min read

PDRN (polydeoxyribonucleotide) is a fragmented DNA-derived compound, typically purified from salmon or trout milt, injected into the skin to support tissue repair rather than to add volume.

Rejuran and comparable polynucleotide boosters are among the most requested injectable treatments in Korean dermatology clinics, yet most patient-facing material describes outcomes without explaining what the molecule is proposed to do. That gap matters, because the mechanism is precisely what tells you which skin problems this treatment can plausibly address and which it cannot. This guide explains the proposed biology in plain terms, summarises what the published evidence currently supports, and sets out realistic expectations. Responses vary between individuals and no injectable produces a guaranteed result.

What PDRN and Polynucleotides Actually Are

PDRN is a mixture of DNA fragments of defined molecular weight range, extracted and purified so that the species-specific genetic information is removed and what remains is the nucleotide building blocks. Polynucleotide (PN) preparations are longer-chain versions of the same class, which form a more gel-like structure in tissue and are often marketed for their additional physical hydrating effect.

Salmon-derived DNA is used because its nucleotide sequence is described as highly homologous to human DNA, which is the stated rationale for low immunogenicity. Importantly, these products are not fillers. They are not designed to occupy space or project tissue. Injecting a polynucleotide booster expecting the volumising effect of hyaluronic acid filler is a category error, and it is the single most common misunderstanding patients bring to consultation.

The Proposed Mechanism: Adenosine A2A Receptor Activation

The most cited proposed mechanism is salvage-pathway activity. As PDRN is broken down in tissue, it releases nucleosides and nucleotides, including adenosine. Adenosine binding at the A2A receptor on fibroblasts and other cells is associated in published work with anti-inflammatory signalling, increased production of growth factors including VEGF, and stimulation of angiogenesis and collagen synthesis.

A second proposed route is the salvage pathway itself: supplying nucleotide fragments is theorised to reduce the metabolic cost of DNA synthesis in cells engaged in repair, supporting fibroblast proliferation. Both mechanisms are consistent with what patients report clinically — improvement in skin texture, elasticity, fine crepey lines, and post-inflammatory redness — and both point away from any expectation of structural or volumetric change. It is worth noting that much of the mechanistic work derives from wound-healing and laboratory models, and that translation to cosmetic outcomes in healthy skin is an area where the evidence base is still developing.

What the Evidence Reasonably Supports

PDRN has an established regulatory history in wound healing and tissue repair indications, and the aesthetic literature includes controlled studies and case series reporting improvements in skin elasticity, hydration, and fine-line appearance following courses of intradermal injection. Reported effect sizes are generally modest and cumulative rather than dramatic.

The limitations of that evidence base should be stated plainly: many aesthetic studies are small, some are industry-associated, follow-up periods are often short, and standardised comparison against other skin-quality treatments is limited. A reasonable summary is that polynucleotide boosters are plausible, generally well tolerated, and supported by encouraging but not definitive aesthetic evidence. Patients should treat claims of transformation with scepticism and claims of gradual textural improvement as credible.

Typical Protocols and Realistic Timelines

A standard course is commonly described as three to four sessions spaced two to four weeks apart, followed by maintenance every four to six months. Injection is intradermal or into the superficial subcutaneous layer, delivered either as multiple microdroplets across the treatment area or via a linear threading technique.

Patients typically report that change is not apparent after a single session, and that the first noticeable difference in texture and light reflection tends to emerge after the second or third. This gradual profile is consistent with a collagen-remodelling mechanism, which operates over weeks to months rather than immediately. Anyone promised a visible result on the day of the first injection is being promised swelling.

Side Effects and Practical Considerations

The most consistently reported effects are injection-related: papules or bumps at injection points lasting one to several days, bruising, transient swelling, and tenderness. Because delivery is intradermal, visible bumps are common enough that clinics routinely advise against scheduling the treatment immediately before a significant event. Allergy is uncommon but relevant for patients with fish allergy, who should disclose this before treatment.

A practical scheduling note for medical travellers: if you are visiting Korea for a limited period, a full course spaced across several weeks is often not achievable in one trip. Discuss with the clinic whether a compressed schedule is appropriate for you, and whether continuation is available in your home country, before beginning a course you cannot complete.

What Most Skin Booster Guides Do Not Say: What PDRN Will Not Fix

The gap in most content on this topic is that it describes what the treatment does without defining its boundaries, which leaves patients to discover the limits after paying for a course.

Polynucleotide boosters are not a volumising treatment and will not correct hollowing, deep folds, or structural descent. They are not a laxity treatment and will not lift a jawline. They are not a primary treatment for established deep wrinkles, and they are not a pigment treatment; melasma and post-inflammatory hyperpigmentation require different mechanisms entirely, typically involving tyrosinase-pathway agents or appropriately selected laser therapy. What PDRN is reasonably positioned to address is skin quality: texture, fine crepey lines, elasticity, hydration, and the general dullness associated with photoaged or dehydrated skin. Matching a treatment to the correct problem is the whole of good aesthetic planning, and this treatment is frequently sold for problems it was never designed to solve.

Frequently Asked Questions

Is Rejuran a filler?

No. It is a skin booster intended to influence skin quality through a repair-associated mechanism, not to occupy space or create projection. Hyaluronic acid fillers and polynucleotide boosters address different problems and are sometimes used together for that reason.

How many sessions are needed before results appear?

Most protocols use three to four sessions two to four weeks apart, and patients commonly report first noticing textural change after the second or third session. A single session is generally not sufficient to assess the treatment.

Are the injection bumps normal?

Small papules at injection points are a frequently reported and expected consequence of intradermal delivery, typically settling within one to several days. Persistent or enlarging nodules should be reviewed by the treating clinic.

Can PDRN be combined with lasers or microneedling?

Combination protocols are common in Korean practice, with sequencing and interval determined by the specific devices used and your skin condition. Combination decisions should be made by the treating clinician rather than assembled by the patient from separate recommendations.

Is it safe for people with a fish allergy?

Because the material is derived from salmon or trout, patients with a known fish allergy should disclose this and discuss suitability before treatment. Allergic reaction is uncommon but the disclosure is important.

Deciding Whether It Fits Your Goals

Before booking a course, define the problem you are trying to solve in one sentence. If that sentence describes texture, fine lines, dullness, or elasticity, a polynucleotide booster is a reasonable option to discuss. If it describes volume, sagging, or pigment, ask the clinic which treatment actually targets that mechanism, and be cautious if the answer is still Rejuran.

Sources and further reading: Korea Health Industry Development Institute (KHIDI) • Korean Society of Plastic and Reconstructive Surgeons • PubMed (peer-reviewed literature)